These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Rapid reduction of extremely high kappa free light chains in a patient with myeloma cast nephropathy. Snozek CLH; Kinard TN; Adamski J J Clin Apher; 2018 Jun; 33(3):439-443. PubMed ID: 29427353 [TBL] [Abstract][Full Text] [Related]
45. The role of immunological assessment in patients with acute kidney injury and possible myeloma. Lachmann HJ; Wassef NL Adv Chronic Kidney Dis; 2012 Sep; 19(5):287-90. PubMed ID: 22920638 [TBL] [Abstract][Full Text] [Related]
46. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. Heyne N; Denecke B; Guthoff M; Oehrlein K; Kanz L; Häring HU; Weisel KC Ann Hematol; 2012 May; 91(5):729-735. PubMed ID: 22170517 [TBL] [Abstract][Full Text] [Related]
47. Experience of using hemodialysis with medium cut-off dialyzer in cast nephropathy. Cazorla López JM; García García-Doncel A; Naranjo Muñoz J; Villanego Fernández F; Vigara Sánchez LA; Ceballos Guerrero M Nefrologia (Engl Ed); 2020; 40(3):367-369. PubMed ID: 32007298 [No Abstract] [Full Text] [Related]
48. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Hutchison CA; Cook M; Heyne N; Weisel K; Billingham L; Bradwell A; Cockwell P Trials; 2008 Sep; 9():55. PubMed ID: 18822172 [TBL] [Abstract][Full Text] [Related]
50. Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney. Grima DT; Airia P; Attard C; Hutchison CA Curr Med Res Opin; 2011 Feb; 27(2):383-91. PubMed ID: 21175375 [TBL] [Abstract][Full Text] [Related]
51. Lambda light chain myeloma with oliguric cast nephropathy and remission with bortezomib, doxorubicin and dexamethasone. Hada R; Poudyal B; Sharma A; Khatri R JNMA J Nepal Med Assoc; 2012; 52(188):192-5. PubMed ID: 23591252 [TBL] [Abstract][Full Text] [Related]
52. High cut-off and high-flux membrane haemodialysis in a patient with rhabdomyolysis-associated acute kidney injury. Albert C; Haase M; Bellomo R; Mertens PR Crit Care Resusc; 2012 Jun; 14(2):159-62. PubMed ID: 22697626 [TBL] [Abstract][Full Text] [Related]
53. Enhanced elimination of cyclophosphamide by high cut-off haemodialysis: single-dose pharmacokinetics in a patient with cast nephropathy. Eden G; Kühn-Velten WN; Hafer C; Kielstein JT BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29301798 [TBL] [Abstract][Full Text] [Related]
54. Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study. Yadav P; Sathick IJ; Leung N; Brown EE; Cook M; Sanders PW; Cockwell P Blood Cancer J; 2020 Mar; 10(3):28. PubMed ID: 32127527 [TBL] [Abstract][Full Text] [Related]
55. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients. Pendón-Ruiz de Mier MV; Ojeda R; Álvarez-Lara MA; Navas A; Alonso C; Caballero-Villarraso J; Aljama P; Álvarez MA; Soriano S; Rodríguez M; Martín-Malo A BMC Nephrol; 2020 Jun; 21(1):227. PubMed ID: 32539688 [TBL] [Abstract][Full Text] [Related]
56. Hemodialysis Using High Cut Off Filters in Light Chain Cast Nephropathy. Buus NH; Rantanen JM; Krag SP; Andersen NF; Jensen JD Blood Purif; 2015; 40(3):223-31. PubMed ID: 26376291 [TBL] [Abstract][Full Text] [Related]
57. Management of acute kidney injury in frail patients with biopsy-proven cast nephropathy: a combined approach with chemotherapy plus Supra-hemodiafiltration with post-adsorption endogenous reinfusion. Murgia S; Quattrocchio G; Forneris G; Pozzato M; Fenoglio R; Ferro M; De Simone E; Del Vecchio G; Di Benedetto C; Roccatello D J Nephrol; 2022 May; 35(4):1243-1249. PubMed ID: 34982413 [TBL] [Abstract][Full Text] [Related]